FLUDEOXYGLUCOSE F18

Post-LOE

fludeoxyglucose f-18

Biomed

ANDAINTRAVENOUSINJECTABLE

Approved

May 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

FLUDEOXYGLUCOSE F18 (fludeoxyglucose f-18) by Biomed is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 2015.

Drug data last refreshed 1w ago

Mechanism of Action

Radiopharmaceutical Activity

Pharmacologic Class:

Radioactive Diagnostic Agent

Indications (1)

Radioactive Diagnostic Agent

Clinical Trials (1)

NCT03493789Phase 1Completed

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

Started Apr 2018

19 enrolled

Stage I Lung CancerStage I Non-Small Cell Lung Cancer AJCC v7Stage IA Non-Small Cell Lung Carcinoma AJCC v7+5 more

Worked on FLUDEOXYGLUCOSE F18 at Biomed? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.